[Management of acromegaly in pregnant woman].
Pregnancy in acromegalic patients is an infrequent event, due to perturbed gonadotroph function. On the other hand, pregnancy may cause an enlargement of the adenoma or an increase of growth hormone (GH) secretion. We report the case of a 26-year-old woman with a GH-secreting pituitary macroadenoma who was operated by transphenoidal approach. After surgery, she had a persistent acromegaly due to an intrasellar tumour. She was treated by lanreotide. After one year, the patient had married and became pregnant. Lanreotide was stopped when the diagnosis of pregnancy was established. The follow-up of this patient showed a progressive increase of IGF1 level during pregnancy without tumoral syndrome or visual troubles. No metabolic complication was detected. The patient went to term and gave birth to a healthy baby. In postpartum, the IGF1 level was normal, but the brain MRI revealed a 10mm intrasellar tumour. The pituitary adenoma was not significantly enlarged during pregnancy. Therefore, pregnancy doesn't influence acromegaly in young women well controlled by medical treatment.
Ben Salem Hachmi
L
L
Service d'endocrinologie et des maladies métaboliques. institut national de nutrition, 11 rue Djebel Lakhdhar, Bas Saadoun, Tunis, Tunisia. leila.bensalem@rns.tn
Kammoun
I
I
Bouzid
C
C
Smida
H
H
Nagi
S
S
Turki
Z
Z
Ben Slama
C
C
D000172:Acromegaly / Q000473:pathology / Q000601:surgery*; D000236:Adenoma / Q000601:surgery*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000473:pathology / Q000601:surgery*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000473:pathology / Q000601:surgery*; D011256:Pregnancy Outcome; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I